Age-related antihypertensive and haemodynamic effects of verapamil SR: Clinical results and effects on atrial natriuretic peptide

R. Antonicelli, P. F. Tomassini, P. Galletti, C. Gambini, M. Marini, L. Amadio, E. Paciaroni

Research output: Contribution to journalArticle

Abstract

The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, <65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p. o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders' rate was 65% in the AH group and 82% in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00 ± 0.51 to 3.25 ± 0.83 ml min-1 m-2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min-1 m-2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated antihypertensive treatment in both adult and elderly patients.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Volume39
Issue number1
DOIs
Publication statusPublished - Oct 1990

Fingerprint

Atrial Natriuretic Factor
Verapamil
Antihypertensive Agents
Hemodynamics
Arterial Pressure
Heart Rate
Calcium
Therapeutics

Keywords

  • atrial natriuretic peptide
  • clinical trial
  • elderly
  • hypertension
  • verapamil haemodynamics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Pharmacology

Cite this

Age-related antihypertensive and haemodynamic effects of verapamil SR : Clinical results and effects on atrial natriuretic peptide. / Antonicelli, R.; Tomassini, P. F.; Galletti, P.; Gambini, C.; Marini, M.; Amadio, L.; Paciaroni, E.

In: European Journal of Clinical Pharmacology, Vol. 39, No. 1, 10.1990.

Research output: Contribution to journalArticle

@article{f991de4761a54160a8c4f8e574bf95a1,
title = "Age-related antihypertensive and haemodynamic effects of verapamil SR: Clinical results and effects on atrial natriuretic peptide",
abstract = "The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, <65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p. o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders' rate was 65{\%} in the AH group and 82{\%} in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00 ± 0.51 to 3.25 ± 0.83 ml min-1 m-2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min-1 m-2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated antihypertensive treatment in both adult and elderly patients.",
keywords = "atrial natriuretic peptide, clinical trial, elderly, hypertension, verapamil haemodynamics",
author = "R. Antonicelli and Tomassini, {P. F.} and P. Galletti and C. Gambini and M. Marini and L. Amadio and E. Paciaroni",
year = "1990",
month = "10",
doi = "10.1007/BF01409204",
language = "English",
volume = "39",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Age-related antihypertensive and haemodynamic effects of verapamil SR

T2 - Clinical results and effects on atrial natriuretic peptide

AU - Antonicelli, R.

AU - Tomassini, P. F.

AU - Galletti, P.

AU - Gambini, C.

AU - Marini, M.

AU - Amadio, L.

AU - Paciaroni, E.

PY - 1990/10

Y1 - 1990/10

N2 - The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, <65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p. o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders' rate was 65% in the AH group and 82% in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00 ± 0.51 to 3.25 ± 0.83 ml min-1 m-2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min-1 m-2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated antihypertensive treatment in both adult and elderly patients.

AB - The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, <65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p. o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders' rate was 65% in the AH group and 82% in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00 ± 0.51 to 3.25 ± 0.83 ml min-1 m-2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min-1 m-2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated antihypertensive treatment in both adult and elderly patients.

KW - atrial natriuretic peptide

KW - clinical trial

KW - elderly

KW - hypertension

KW - verapamil haemodynamics

UR - http://www.scopus.com/inward/record.url?scp=0025013815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025013815&partnerID=8YFLogxK

U2 - 10.1007/BF01409204

DO - 10.1007/BF01409204

M3 - Article

C2 - 2148149

AN - SCOPUS:0025013815

VL - 39

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -